BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$332,00
0,00%
(0,00) 1D
14 ກ.ຍ., 10 ໂມງ 26 ນາທີ 58 ວິນາທີ GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMYB34...
Mkt. cap
໑໒໘,໘໑ ຕື້
Avg. vol.
໗໖,໐໐
Volume
໐,໐໐
52-wk high
R$349,41
52-wk low
R$223,16
Shares outstanding
໒,໐໔ ຕື້
No. of employees
໓໒ ພັນ
Mkt. cap
໑໒໘,໘໑ ຕື້
Avg. vol.
໗໖,໐໐
Volume
໐,໐໐
52-wk high
R$349,41
52-wk low
R$223,16
Shares outstanding
໒,໐໔ ຕື້
No. of employees
໓໒ ພັນ
News stories
From web sources and news partners
AD HOC NEWS
·
2 ຊົ່ວໂມງກ່ອນ
Bristol Myers Squibb stock holds near USD 63 as investors look to October 29 results
AD HOC NEWS
·
2 ຊົ່ວໂມງກ່ອນ
Bristol-Myers Squibb stock holds steady as analysts adjust price targets
MarketBeat
·
3 ຊົ່ວໂມງກ່ອນ
Nykredit A S Acquires New Holdings in Bristol Myers Squibb Company $BMY
Yahoo Finance
·
1 ມື້ກ່ອນ
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32,5 ພັນ
Founded1887
Headquartersນິວຢອກ, ລັດນີວຢອກ, ສະຫະລັດ
SectorPharmaceutical industry
Websitebms.com